Spectrochim Acta A Mol Biomol Spectrosc
January 2024
A new nitropyridine amino N-oxide derivative 2-[(4-nitropyridine-3-yl)amino]ethan-1-ol N-oxide was synthesized and its structural and optical properties were described. Its structure obtained from the X-ray diffraction (XRD) studies was related to the Infrared spectroscopy (IR), Raman spectroscopy (RS), electron Ultraviolet-Visible spectroscopy (UV-VIS) and emission spectra measurements. The experimental results were analyzed in terms of theoretical data obtained from quantum chemical Density Functional Theory (DFT) and Natural Bond Orbital (NBO) calculations.
View Article and Find Full Text PDFMembranes produced by crosslinking chitosan with magnesium phytate were prepared using highly deacetylated chitosan and its -carboxymethyl, -carboxymethyl and ,-carboxymethyl derivatives. The conditions of the membrane production were described. IR, Raman, electron absorption and emission spectra were measured and analyzed for all the substrates.
View Article and Find Full Text PDFFor this study, the thermal degradation of palm, coconut, rice bran, and rapeseed (canola) oils was studied. Products formed during deep-frying were identified using chemical methods and these results were verified with those derived from FT-IR (Fourier-transform infrared spectroscopy) studies. Mathematically processed spectral data were analyzed in terms of the breaking of double bonds, the decomposition of the carotenoids, and the reduction of the C=O carbonyl group.
View Article and Find Full Text PDFThe crystal and molecular structure and physicochemical properties of 2--methylamino-3-methylpyridine -oxide (MA3MPO) have been studied. MA3MPO was synthesized from 2-amino-3-methylpyridine by several steps to form colorless crystals suitable for crystallographic analysis. The data reveal that MA3MPO crystallizes in the monoclinic space group 2/.
View Article and Find Full Text PDFBackground: The optimal EBRT schedule for MSCC is undetermined. Our aim was to determine whether a single fraction (SF) was non-inferior to five daily fractions (5Fx), for functional motor outcome.
Methods: Patients not proceeding with surgical decompression in this multicentre non-inferiority, Phase 3 trial were randomised to 10 Gy/SF or 20 Gy/5Fx.